Q4e: Clean EBIT of PLN 87m Paper markets still weak, but demand better Fair value range of SEK 40-80...
Det svenska sensorteknikbolaget JonDeTech Sensors AB (”JonDeTech” eller ”Bolaget”) designar, produce...
Redeye comments on Sleep Cycle’s announcement this morning regarding its strategic move to consolida...
Redeye comments on the directed share issue that completes the previous rights issue.
Q4 report due Friday, 23 February at 07:00 CET 6.0-9.
Q4 report due 29 Feb Q4'23e net sales of SEK 464m, EBITA of SEK 59m We estimate the fair value at SE...
Redeye endorses today’s news that Curasight has received the first milestone payment from Curium and...
Equity analyst Markus Almerud interviews Maha’s CEO Kjetil Solbraekke about the acquisition of 5% of...
Redeye leave a comment on Xbrane following today's announcement of a SEK343m rights issue of units.
'23e-'25e EBITA down 8-3% Gross margin recovery hampered by Red Sea tensions '24e-'25e lease adj.
Redeye makes minor adjustements to its valuation of InDex Pharmaceuticals following the announcement...
Q4e: Two deliveries, sales only SEK 3.6m due to payment model '24e the year of e-MELT ID, '25e the y...
The Palex group of 800 professionals with a long history as a leading provider of advanced solutions...
We update our model after recent share issues... ..
Etteplan gave a profit warning as its EBIT fell short of expectations in Q4.
Duell's results exceeded our estimates for revenue and adj.
Q4'23 results due 6 February Instrument sales to drive growth in Q4e 27-33% below historical NTM P/E...
Q4e: sales of SEK 30m, up 37% y-o-y, adj. EBIT SEK -5m (-20m) Turning our eyes to '24e, where we exp...
Expect strong Q4 sales after order intake surprise in Q3 Estimates unchanged, growth and margin expa...
Q4e: sales SEK 50m, up +9% q-o-q, EBIT -2m (-4m) Minor estimate changes, eyeing profitable growth in...
